Buchumschlag

VINCENT: a randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML

For younger, medically fit patients with NPM1-mutated, FLT3-wildtype acute myeloid leukemia (AML) intensive chemotherapy represents standard of care (SOC), with complete remission (CR) rates observed in up to 85% of patients and 5-year overall survival (OS) rates of 40-50%. However, significant toxi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kretschmer, Lydia (VerfasserIn) , Ruhnke, Leo (VerfasserIn) , Schliemann, Christoph (VerfasserIn) , Fransecky, Lars (VerfasserIn) , Steffen, Björn (VerfasserIn) , Kaufmann, Martin (VerfasserIn) , Burchert, Andreas (VerfasserIn) , Schmid, Christoph (VerfasserIn) , Hanoun, Maher (VerfasserIn) , Sauer, Tim (VerfasserIn) , Metzeler, Klaus H. (VerfasserIn) , Schäfer-Eckart, Kerstin (VerfasserIn) , Hänel, Mathias (VerfasserIn) , Crysandt, Martina (VerfasserIn) , Jäger, Paul (VerfasserIn) , Krause, Stefan W. (VerfasserIn) , Dierks, Christine (VerfasserIn) , Klein, Stefan (VerfasserIn) , Maguire, Nadia (VerfasserIn) , Frenzel, Lukas P. (VerfasserIn) , Bücklein, Veit L. (VerfasserIn) , Blau, Wolfgang (VerfasserIn) , Kaiser, Ulrich (VerfasserIn) , Wegehenkel, Kai (VerfasserIn) , Höllein, Alexander (VerfasserIn) , Seggewiss-Bernhardt, Ruth (VerfasserIn) , Markgraf, Wenke (VerfasserIn) , Fiebig, Frank (VerfasserIn) , Harig, Anna (VerfasserIn) , Schmidt-Brücken, Katharina (VerfasserIn) , Thiede, Christian (VerfasserIn) , Middeke, Jan Moritz (VerfasserIn) , Dillon, Richard (VerfasserIn) , Baldus, Claudia D. (VerfasserIn) , Serve, Hubert (VerfasserIn) , Spiekermann, Karsten (VerfasserIn) , Hiddemann, Wolfgang (VerfasserIn) , Schlenk, Richard F. (VerfasserIn) , Müller-Tidow, Carsten (VerfasserIn) , Bornhäuser, Martin (VerfasserIn) , Röllig, Christoph (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: July 2025
In: Annals of hematology
Year: 2025, Jahrgang: 104, Heft: 7, Pages: 3647-3654
ISSN:1432-0584
DOI:10.1007/s00277-025-06496-7
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00277-025-06496-7
Verlag, kostenfrei, Volltext: http://link.springer.com/article/10.1007/s00277-025-06496-7
Resolving-System, kostenfrei: https://doi.org/10.25673/120875
Volltext
Verfasserangaben:Lydia Kretschmer, Leo Ruhnke, Christoph Schliemann, Lars Fransecky, Björn Steffen, Martin Kaufmann, Andreas Burchert, Christoph Schmid, Maher Hanoun, Tim Sauer, Klaus H. Metzeler, Kerstin Schäfer-Eckart, Mathias Hänel, Martina Crysandt, Paul Jäger, Stefan W. Krause, Christine Dierks, Stefan Klein, Nadia Maguire, Lukas P. Frenzel, Veit L. Bücklein, Wolfgang Blau, Ulrich Kaiser, Kai Wegehenkel, Alexander Höllein, Ruth Seggewiss-Bernhardt, Wenke Markgraf, Frank Fiebig, Anna Harig, Katharina Schmidt-Brücken, Christian Thiede, Jan Moritz Middeke, Richard Dillon, Claudia D. Baldus, Hubert Serve, Karsten Spiekermann, Wolfgang Hiddemann, Richard F. Schlenk, Carsten Müller-Tidow, Martin Bornhäuser, Christoph Röllig

MARC

LEADER 00000caa a2200000 c 4500
001 1935580167
003 DE-627
005 20251017074134.0
007 cr uuu---uuuuu
008 250911s2025 xx |||||o 00| ||eng c
024 7 |a 10.1007/s00277-025-06496-7  |2 doi 
024 7 |a 10.25673/120875  |2 doi 
035 |a (DE-627)1935580167 
035 |a (DE-599)KXP1935580167 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Kretschmer, Lydia  |e VerfasserIn  |0 (DE-588)1376143089  |0 (DE-627)1935580426  |4 aut 
245 1 0 |a VINCENT  |b a randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML  |c Lydia Kretschmer, Leo Ruhnke, Christoph Schliemann, Lars Fransecky, Björn Steffen, Martin Kaufmann, Andreas Burchert, Christoph Schmid, Maher Hanoun, Tim Sauer, Klaus H. Metzeler, Kerstin Schäfer-Eckart, Mathias Hänel, Martina Crysandt, Paul Jäger, Stefan W. Krause, Christine Dierks, Stefan Klein, Nadia Maguire, Lukas P. Frenzel, Veit L. Bücklein, Wolfgang Blau, Ulrich Kaiser, Kai Wegehenkel, Alexander Höllein, Ruth Seggewiss-Bernhardt, Wenke Markgraf, Frank Fiebig, Anna Harig, Katharina Schmidt-Brücken, Christian Thiede, Jan Moritz Middeke, Richard Dillon, Claudia D. Baldus, Hubert Serve, Karsten Spiekermann, Wolfgang Hiddemann, Richard F. Schlenk, Carsten Müller-Tidow, Martin Bornhäuser, Christoph Röllig 
264 1 |c July 2025 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 11.09.2025 
520 |a For younger, medically fit patients with NPM1-mutated, FLT3-wildtype acute myeloid leukemia (AML) intensive chemotherapy represents standard of care (SOC), with complete remission (CR) rates observed in up to 85% of patients and 5-year overall survival (OS) rates of 40-50%. However, significant toxicity and need for hospitalization pose challenges on patients’ outcome and quality of life (QoL). Venetoclax (VEN) combined with azacitidine (AZA) has demonstrated encouraging efficacy in older, unfit AML patients, achieving high CR/CRi rates and promising OS with lower toxicity. Prospective, randomized data comparing VEN/AZA to SOC in younger, fit patients are currently missing. VINCENT is a randomized-controlled, multicenter, non-inferiority, phase 2 trial (NCT05904106) evaluating VEN/AZA versus SOC in adults aged 18-70 years with newly diagnosed, NPM1-mutated, FLT3-wildtype AML. Patients medically fit for intensive chemotherapy (ECOG ≤ 2) with adequate organ function are eligible, while patients with relapsed/refractory AML or prior cytotoxic treatment are excluded. A total of 146 patients will be randomized 1:1 to receive either VEN/AZA or SOC. Hematologic remission is evaluated according to ELN 2022 guidelines. The primary endpoint is the modified event-free survival, defined as either primary induction failure, hematologic relapse, molecular failure or death. Secondary endpoints include safety, tolerability, CR/CRi/CRh/CRMRD− rates, MRD kinetics (using NPM1 RT-qPCR and MFC), relapse-free survival, OS, early mortality, health-related QoL and cumulative health-care-resource use. Patients will be followed up for at least two years post enrollment. The VINCENT trial will be the first study to provide comprehensive prospective data comparing VEN/AZA to SOC, addressing both efficacy and patient-centered outcomes. 
540 |q DE-3  |a Namensnennung 4.0 International  |f CC BY 4.0  |2 cc  |u https://creativecommons.org/licenses/by/4.0/ 
700 1 |a Ruhnke, Leo  |e VerfasserIn  |4 aut 
700 1 |a Schliemann, Christoph  |e VerfasserIn  |4 aut 
700 1 |a Fransecky, Lars  |e VerfasserIn  |4 aut 
700 1 |a Steffen, Björn  |e VerfasserIn  |4 aut 
700 1 |a Kaufmann, Martin  |e VerfasserIn  |4 aut 
700 1 |a Burchert, Andreas  |e VerfasserIn  |4 aut 
700 1 |a Schmid, Christoph  |e VerfasserIn  |4 aut 
700 1 |a Hanoun, Maher  |e VerfasserIn  |4 aut 
700 1 |a Sauer, Tim  |e VerfasserIn  |4 aut 
700 1 |a Metzeler, Klaus H.  |e VerfasserIn  |4 aut 
700 1 |a Schäfer-Eckart, Kerstin  |e VerfasserIn  |4 aut 
700 1 |a Hänel, Mathias  |e VerfasserIn  |4 aut 
700 1 |a Crysandt, Martina  |e VerfasserIn  |4 aut 
700 1 |a Jäger, Paul  |e VerfasserIn  |4 aut 
700 1 |a Krause, Stefan W.  |e VerfasserIn  |4 aut 
700 1 |a Dierks, Christine  |e VerfasserIn  |4 aut 
700 1 |a Klein, Stefan  |e VerfasserIn  |0 (DE-588)1042491836  |0 (DE-627)769066372  |0 (DE-576)393988791  |4 aut 
700 1 |a Maguire, Nadia  |e VerfasserIn  |4 aut 
700 1 |a Frenzel, Lukas P.  |e VerfasserIn  |4 aut 
700 1 |a Bücklein, Veit L.  |e VerfasserIn  |4 aut 
700 1 |a Blau, Wolfgang  |e VerfasserIn  |4 aut 
700 1 |a Kaiser, Ulrich  |e VerfasserIn  |4 aut 
700 1 |a Wegehenkel, Kai  |e VerfasserIn  |4 aut 
700 1 |a Höllein, Alexander  |e VerfasserIn  |4 aut 
700 1 |a Seggewiss-Bernhardt, Ruth  |e VerfasserIn  |4 aut 
700 1 |a Markgraf, Wenke  |e VerfasserIn  |4 aut 
700 1 |a Fiebig, Frank  |e VerfasserIn  |4 aut 
700 1 |a Harig, Anna  |e VerfasserIn  |4 aut 
700 1 |a Schmidt-Brücken, Katharina  |e VerfasserIn  |4 aut 
700 1 |a Thiede, Christian  |e VerfasserIn  |4 aut 
700 1 |a Middeke, Jan Moritz  |e VerfasserIn  |4 aut 
700 1 |a Dillon, Richard  |e VerfasserIn  |4 aut 
700 1 |a Baldus, Claudia D.  |e VerfasserIn  |4 aut 
700 1 |a Serve, Hubert  |e VerfasserIn  |4 aut 
700 1 |a Spiekermann, Karsten  |e VerfasserIn  |4 aut 
700 1 |a Hiddemann, Wolfgang  |e VerfasserIn  |4 aut 
700 1 |a Schlenk, Richard F.  |e VerfasserIn  |4 aut 
700 1 |a Müller-Tidow, Carsten  |e VerfasserIn  |4 aut 
700 1 |a Bornhäuser, Martin  |e VerfasserIn  |4 aut 
700 1 |a Röllig, Christoph  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Annals of hematology  |d Berlin : Springer, 1991  |g 104(2025), 7 vom: Juli, Seite 3647-3654  |h Online-Ressource  |w (DE-627)253389852  |w (DE-600)1458429-3  |w (DE-576)072283157  |x 1432-0584  |7 nnas  |a VINCENT a randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML 
773 1 8 |g volume:104  |g year:2025  |g number:7  |g month:07  |g pages:3647-3654  |g extent:8  |a VINCENT a randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML 
856 4 0 |u https://doi.org/10.1007/s00277-025-06496-7  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u http://link.springer.com/article/10.1007/s00277-025-06496-7  |x Verlag  |z kostenfrei  |3 Volltext 
856 4 0 |u https://doi.org/10.25673/120875  |x Resolving-System  |z kostenfrei 
951 |a AR 
992 |a 20250911 
993 |a Article 
994 |a 2025 
998 |g 1042491836  |a Klein, Stefan  |m 1042491836:Klein, Stefan  |d 60000  |e 60000PK1042491836  |k 0/60000/  |p 18 
999 |a KXP-PPN1935580167  |e 4770863217 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1007/s00277-025-06496-7","10.25673/120875"],"eki":["1935580167"]},"physDesc":[{"extent":"8 S."}],"relHost":[{"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Annals of hematology","subtitle":"organ of: Gesellschaft für Thrombose- und Hämostaseforschung, DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie e.V., ÖGHO, Österreichische Gesellschaft für Hämatologie und Onkologie","title":"Annals of hematology"}],"disp":"VINCENT a randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AMLAnnals of hematology","note":["Gesehen am 24.04.2025","Fortsetzung der Druck-Ausgabe","Ungezählte Beil. ab 80.2001: Supplement"],"type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"eki":["253389852"],"zdb":["1458429-3"],"issn":["1432-0584"]},"part":{"pages":"3647-3654","issue":"7","text":"104(2025), 7 vom: Juli, Seite 3647-3654","volume":"104","year":"2025","extent":"8"},"pubHistory":["62, 1 (Februrary 1991)-"],"recId":"253389852","titleAlt":[{"title":"Hematology"}],"origin":[{"dateIssuedKey":"1991","publisherPlace":"Berlin ; Heidelberg ; New York","publisher":"Springer","dateIssuedDisp":"1991-"}]}],"title":[{"title":"VINCENT","subtitle":"a randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML","title_sort":"VINCENT"}],"language":["eng"],"person":[{"display":"Kretschmer, Lydia","role":"aut","family":"Kretschmer","given":"Lydia"},{"family":"Ruhnke","given":"Leo","display":"Ruhnke, Leo","role":"aut"},{"role":"aut","display":"Schliemann, Christoph","given":"Christoph","family":"Schliemann"},{"family":"Fransecky","given":"Lars","display":"Fransecky, Lars","role":"aut"},{"role":"aut","display":"Steffen, Björn","given":"Björn","family":"Steffen"},{"role":"aut","display":"Kaufmann, Martin","given":"Martin","family":"Kaufmann"},{"given":"Andreas","family":"Burchert","role":"aut","display":"Burchert, Andreas"},{"display":"Schmid, Christoph","role":"aut","family":"Schmid","given":"Christoph"},{"family":"Hanoun","given":"Maher","display":"Hanoun, Maher","role":"aut"},{"given":"Tim","family":"Sauer","role":"aut","display":"Sauer, Tim"},{"role":"aut","display":"Metzeler, Klaus H.","given":"Klaus H.","family":"Metzeler"},{"given":"Kerstin","family":"Schäfer-Eckart","role":"aut","display":"Schäfer-Eckart, Kerstin"},{"family":"Hänel","given":"Mathias","display":"Hänel, Mathias","role":"aut"},{"display":"Crysandt, Martina","role":"aut","family":"Crysandt","given":"Martina"},{"given":"Paul","family":"Jäger","role":"aut","display":"Jäger, Paul"},{"family":"Krause","given":"Stefan W.","display":"Krause, Stefan W.","role":"aut"},{"display":"Dierks, Christine","role":"aut","family":"Dierks","given":"Christine"},{"display":"Klein, Stefan","role":"aut","family":"Klein","given":"Stefan"},{"given":"Nadia","family":"Maguire","role":"aut","display":"Maguire, Nadia"},{"given":"Lukas P.","family":"Frenzel","role":"aut","display":"Frenzel, Lukas P."},{"role":"aut","display":"Bücklein, Veit L.","given":"Veit L.","family":"Bücklein"},{"display":"Blau, Wolfgang","role":"aut","family":"Blau","given":"Wolfgang"},{"role":"aut","display":"Kaiser, Ulrich","given":"Ulrich","family":"Kaiser"},{"display":"Wegehenkel, Kai","role":"aut","family":"Wegehenkel","given":"Kai"},{"family":"Höllein","given":"Alexander","display":"Höllein, Alexander","role":"aut"},{"display":"Seggewiss-Bernhardt, Ruth","role":"aut","family":"Seggewiss-Bernhardt","given":"Ruth"},{"display":"Markgraf, Wenke","role":"aut","family":"Markgraf","given":"Wenke"},{"role":"aut","display":"Fiebig, Frank","given":"Frank","family":"Fiebig"},{"role":"aut","display":"Harig, Anna","given":"Anna","family":"Harig"},{"family":"Schmidt-Brücken","given":"Katharina","display":"Schmidt-Brücken, Katharina","role":"aut"},{"given":"Christian","family":"Thiede","role":"aut","display":"Thiede, Christian"},{"given":"Jan Moritz","family":"Middeke","role":"aut","display":"Middeke, Jan Moritz"},{"role":"aut","display":"Dillon, Richard","given":"Richard","family":"Dillon"},{"role":"aut","display":"Baldus, Claudia D.","given":"Claudia D.","family":"Baldus"},{"given":"Hubert","family":"Serve","role":"aut","display":"Serve, Hubert"},{"family":"Spiekermann","given":"Karsten","display":"Spiekermann, Karsten","role":"aut"},{"family":"Hiddemann","given":"Wolfgang","display":"Hiddemann, Wolfgang","role":"aut"},{"given":"Richard F.","family":"Schlenk","role":"aut","display":"Schlenk, Richard F."},{"role":"aut","display":"Müller-Tidow, Carsten","given":"Carsten","family":"Müller-Tidow"},{"given":"Martin","family":"Bornhäuser","role":"aut","display":"Bornhäuser, Martin"},{"role":"aut","display":"Röllig, Christoph","given":"Christoph","family":"Röllig"}],"origin":[{"dateIssuedDisp":"July 2025","dateIssuedKey":"2025"}],"name":{"displayForm":["Lydia Kretschmer, Leo Ruhnke, Christoph Schliemann, Lars Fransecky, Björn Steffen, Martin Kaufmann, Andreas Burchert, Christoph Schmid, Maher Hanoun, Tim Sauer, Klaus H. Metzeler, Kerstin Schäfer-Eckart, Mathias Hänel, Martina Crysandt, Paul Jäger, Stefan W. Krause, Christine Dierks, Stefan Klein, Nadia Maguire, Lukas P. Frenzel, Veit L. Bücklein, Wolfgang Blau, Ulrich Kaiser, Kai Wegehenkel, Alexander Höllein, Ruth Seggewiss-Bernhardt, Wenke Markgraf, Frank Fiebig, Anna Harig, Katharina Schmidt-Brücken, Christian Thiede, Jan Moritz Middeke, Richard Dillon, Claudia D. Baldus, Hubert Serve, Karsten Spiekermann, Wolfgang Hiddemann, Richard F. Schlenk, Carsten Müller-Tidow, Martin Bornhäuser, Christoph Röllig"]},"recId":"1935580167","note":["Gesehen am 11.09.2025"]} 
SRT |a KRETSCHMERVINCENT2025 

Ähnliche Einträge